Tactile Medical reports ‘broad-based’ performance
By HME News Staff
Updated 9:39 AM CDT, Wed May 6, 2026
MINNEAPOLIS, Minn. – Tactile Systems Technology reported total revenue of $75.3 million for the first quarter ended March 31, 2026, an increase of 23% year-over-year. Net loss was $1.8 million vs. $3 million, and adjusted EBITDA was $3.7 million vs. $0.3 million. “We delivered a strong start to 2026, with first quarter revenue growth of 23% year-over-year driven by disciplined execution of our strategic priorities,” said Sheri Dodd, CEO. “Performance in the quarter was broad-based and reflected the strength and durability of our go-to-market strategy, including increased productivity from a fully resourced sales organization, growing access to advanced therapy under the NCD, and continued momentum across both lymphedema and airway clearance. Importantly, this top line strength translated into meaningful expansion in gross margin and adjusted EBITDA, underscoring the operating leverage in our model.”
Company highlights in the quarter:
- Expanded AI-enabled order management platform with the implementation of new operational capabilities to execute the Medicare prior authorization requirement for PCDs
- Repurchased $1.1 million of stock under the company’s share repurchase program
- Received FDA 510(k) clearance for next-generation AffloVest airway clearance device
Related: Tactile Medical uses heat maps to drive payer policy changes.
Comments